HER2-negative breast cancer
Oncology · 2023–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| olaparib Treatment of human epidermal growth factor 2 (HER2)-negative metastatic breast cancer in patients with a confirmed BRCA1 or BRCA2 pathogenic variant who have… | Jul 2024 | Recommended with restriction | input received Breast Cancer Network Australia · Medical Oncology Group |
| olaparib Adjuvant treatment of HER2-negative high-risk early breast cancer with confirmed germline BRCA1 or BRCA2 mutation in patients who have previously been treated… | Mar 2023 | Not recommended | 13 individuals Medical Oncology Group · Breast Cancer Network Australia · Rare Cancers Australia |
Who spoke
Breast Cancer Network Australia · Medical Oncology Group · Rare Cancers Australia
What the PBS pays
$61M in government benefit over 2024–25, across 9,438 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| olaparib | $60.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.